- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06010680
A Study to Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult Volunteers
January 30, 2024 updated by: Jiangsu HengRui Medicine Co., Ltd.
Phase I Clinical Trial of Substance Balance of [14C]SHR2554 in Healthy Chinese Subjects
Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult Male Volunteers.
Study Overview
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: FEN YAO
- Phone Number: 0518-82342973
- Email: fen.yao.fy3@hengrui.com
Study Contact Backup
- Name: ZHENYU ZHU
- Phone Number: 0518-82342973
- Email: zhenyu.zhu@hengrui.com
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215008
- The first affiliated hospital of suzhou University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy adult males between 18 and 45 years;
- Total Body weight ≥50 kg, and the body mass index (BMI) of 19 to 26 kg/m2;
- Sign the informed consent form prior to the trial and have a full understanding of the trial's procedures, content, and potential adverse reactions;
- Ability to communicate effectively with the researchers and comply with the trial requirements.
Exclusion Criteria:
- Comprehensive physical examination, vital signs, laboratory tests, 12-lead ECG, chest X-ray (posteroanterior), anal digital examination, abdominal ultrasound with clinically significant abnormalities as determined by the investigator;
- Resting corrected QT interval (QTcF) >450 ms as obtained from the 12-lead ECG (Note: QTcF interval must be calculated according to Fridericia's method);
- Positive results in any of the following tests: hepatitis B surface antigen or hepatitis B e antigen, hepatitis C virus antibodies or HIV antigen/antibody combination test (HIV-Ag/Ab);
- Clinically significant abnormalities in ophthalmic examination (slit lamp, intraocular pressure, and fundus photography);
- Have taken any clinical trial drug or participated in any clinical trial within 3 months before administration;
- CYP3A4 inducers or inhibitors were taken within 30 days before administration;
- Have taken any prescription or over-the-counter drugs, vitamin products, health care drugs or traditional Chinese medicines within 14 days before administration;
- History of any clinically significant medical conditions or conditions that the investigator deems may affect the trial results, including but not limited to cardiovascular, respiratory, endocrine, nervous, digestive, urinary, immune, mental, and metabolic diseases;
- History of organic heart disease, congestive heart failure, myocardial infarction, angina pectoris, unexplained history of arrhythmia, history of torsades de pointes, history of ventricular tachycardia, atrioventricular conduction block, history of QT prolongation syndrome, or family history of QT prolongation syndrome (confirmed by genetic testing or sudden cardiac death in a close relative at a young age due to cardiac reasons);
- Those who have undergone major surgery within 6 months before administration or that surgical incision has not completely healed; Major surgery includes, but is not limited to, any surgery that is at significant risk of bleeding, prolongs the period of general anesthesia, or has an incision biopsy or significant traumatic injury;
- Hemorrhoids or anal diseases accompanied by regular/ongoing rectal bleeding; inability to swallow or a history of gastrointestinal dysfunction such as irritable bowel syndrome, inflammatory bowel disease, or previous gastric resection surgery that may affect drug absorption as determined by the investigator;
- Allergic predisposition, such as known history of allergy to two or more substances; or deemed by the investigator to be potentially allergic to the investigational drug or its excipients;
- Habitual constipation or diarrhea;
- History of alcoholism with alcohol consumption over 14 units per week; and can't abstain from smoking and alcohol during the study;
- Heavy smoker or habitually use nicotine-containing products;
- Have a history of drug abuse or have used soft drugs (such as: marijuana) within 3 months before administration or take drugs (such as cocaine, amphetamines, phencyclidine, etc.) within 1 year before administration; or positive urine drug abuse test during screening periods;
- Habitual consumption of grapefruit juice or excessive tea, coffee and/or caffeinated beverages (more than 8 cups a day, 1 cup = 250 mL) and unable to quit during the study period;
- Those who cannot tolerate venipuncture or with a history of needle-sickness and blood-sickness;
- Workers who require long-term exposure to radioactive conditions; or those who have significant radiation exposure (≥ 2 chest/abdominal CT scans, or ≥3 other X-ray tests) within 1 year prior to administration or who have participated in radiopharmaceutical labeling tests;
- Blood donation no less than 400 mL or have blood transfusion within 3 months of dosing;
- Vaccination within one month prior to screening or planning to be vaccinated during the trial;
- Intention to conceive or donate sperm during the trial period or within one year after completing the trial, or refusal to strictly adhere to contraceptive measures by the participant and their spouse/partner from the time of signing the informed consent form until one year after completing the trial;
- Subjects who, in the opinion of the Investigator should not participate in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: [14C]SHR2554
|
Patients will receive single dose of orally [14C]SHR2554 on Day 1.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Radioactivity AUC
Time Frame: 0-240 hours
|
0-240 hours
|
Radioactivity Tmax
Time Frame: 0-240 hours
|
0-240 hours
|
Radioactivity Cmax
Time Frame: 0-240 hours
|
0-240 hours
|
Radioactivity t1/2
Time Frame: 0-240 hours
|
0-240 hours
|
Cumulative recovery and recovery rate of total radioactive substance in urine and feces
Time Frame: 0-288 hours
|
0-288 hours
|
Percentage of parent drug and its metabolites in plasma as a percentage of total radioactive exposure (%AUC)
Time Frame: 0-240 hours
|
0-240 hours
|
Percentage of parent drug and its metabolites in urine and feces as a percentage of administered dose (%Dose)
Time Frame: 0-288 hours
|
0-288 hours
|
Radioactivity CL/F
Time Frame: 0-240 hours
|
0-240 hours
|
Radioactivity Vz/F
Time Frame: 0-240 hours
|
0-240 hours
|
1Total radioactivity ratio for blood/plasma
Time Frame: 0-72 hours
|
0-72 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma SHR2554: Tmax
Time Frame: 0-240 hours
|
0-240 hours
|
Plasma SHR2554: Cmax
Time Frame: 0-240 hours
|
0-240 hours
|
Plasma SHR2554: AUC
Time Frame: 0-240 hours
|
0-240 hours
|
Plasma SHR2554: t1/2
Time Frame: 0-240 hours
|
0-240 hours
|
Plasma SHR2554: CL/F
Time Frame: 0-240 hours
|
0-240 hours
|
Plasma SHR2554: Vz/F
Time Frame: 0-240 hours
|
0-240 hours
|
Plasma SHR2554: λz
Time Frame: 0-240 hours
|
0-240 hours
|
AEs and SAEs
Time Frame: 0-12 days
|
0-12 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 7, 2023
Primary Completion (Actual)
November 27, 2023
Study Completion (Actual)
November 27, 2023
Study Registration Dates
First Submitted
August 20, 2023
First Submitted That Met QC Criteria
August 20, 2023
First Posted (Actual)
August 24, 2023
Study Record Updates
Last Update Posted (Actual)
February 1, 2024
Last Update Submitted That Met QC Criteria
January 30, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- SHR2554-I-111
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell LymphomaUnited States
-
Novartis PharmaceuticalsCompletedDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaUnited States, Belgium, Germany, France, Italy, Korea, Republic of, Spain, Turkey
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
Clinical Trials on [14C]SHR2554
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPeripheral T-cell Lymphoma
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingRelapsed/Refractory PTCLT With at Least One Line of Prior Systemic TherapyChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingFollicular LymphomaChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.TerminatedProstate Cancer | Castration-resistant Prostate CancerChina
-
Chinese PLA General HospitalRecruitingRelapsed or Refractory Hodgkin LymphomaChina
-
Chinese PLA General HospitalRecruitingLymphoma | Solid TumorChina
-
Indivior Inc.CompletedOpioid Use DisorderUnited States